Advanced Thymoma (Stage IVB) When Second-Line Chemotherapy Has Not Controlled Disease
Clinical Scenario
This protocol applies to patients with advanced, non-resectable, non-irradiable or metastatic thymoma at Masaoka-Koga stage IVB. In this setting, chemotherapy is the primary treatment modality, as surgery and radiotherapy are no longer feasible options.
Prior Treatment — Failure Condition
This subsequent line is indicated when second-line chemotherapy — which may have included regimens such as carboplatin plus paclitaxel, a platinum plus etoposide combination, or capecitabine plus gemcitabine — has failed to achieve tumour shrinkage and relief of tumour-related symptoms as assessed by RECIST v1.1 criteria.
Treatment Approach (Partial Overview)
For disease that has progressed after second-line chemotherapy, the evidence supports several subsequent-line options — including single-agent cytotoxic therapy and, in selected patients, somatostatin analogue-based approaches. The complete regimen selection criteria, sequencing guidance, and any off-label considerations are detailed in the full protocol.
Treatment Goals
The primary objectives are tumour shrinkage and relief of tumour-related symptoms. Response is assessed using RECIST v1.1 criteria.
References
DOI: 10.1093/annonc/mdv277
- Chemotherapy should be offered as single modality treatment in advanced, non-resectable, non-irradiable or metastatic (stage IVB) thymic epithelial tumours.
- Options for subsequent lines include pemetrexed [III, B] and oral etoposide.
- In patients with octreoscan-positive thymoma not eligible to receive additional chemotherapy, octreotide alone or with prednisone may represent a valuable option [III, B].
- Everolimus may, therefore, represent an off-label option for refractory tumours [III, B].
- Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 criteria should be used to assess response to chemotherapy [V, A].
View source ↗